Almost two decades ago Europe pioneered biosimilars - with the first approval and launch of a biosimilar worldwide. Biosimilar are on the rise, since then the European Commission has approved over 100 biosimilars.
Biosimilars are instrumental to ensuring and expanding patient access to biologic medicines and are critical to the long-term sustainability of healthcare systems.
How to keep Europe on the Map?
The Slovenian Ministry of the Economy, Tourism, and Sport, in partnership with Sandoz, the pioneer and global leader in biosimilars, invites you to join the discussion in person (limited seats) or online on November 8th. You will hear learn more about:
- reasons and opportunities why Europe should remain a key actor in the manufacturing of these critical medicines.
- (untapped) potential of European biosimilar manufacturing, including in the light of the upcoming European Biotech Act, and
- other critical issues such as the role of supply in securing this EU-based manufacturing capacity and the importance of a fit-for-purpose SPC manufacturing exemption as an example
Leading the discussion
The discussion will feature key high-level speakers:
- Matevž Frangež, State Secretary at the Ministry of the Economy, Tourism and Sport of Slovenia.
- MEP Tomislav Sokol (EPP, HR), Shadow Rapporteur for the Directive on Medicinal products for human use, European Parliament.
- Giulia Del Brenna, Head of Unit GROW F.3 (Food, Retail, Health) at the European Commission.
- Antonella Cardone, CEO of the Cancer Patients Europe
- Anne Marie de Jonge-Schuermans, Head of Biologics & Injectables Operations at Sandoz
- Moderated by Adrian van den Hoven, Director General of Medicines for Europe.
The event will take place just before the Global Biosimilars Week, so it's the perfect time to address what needs to be done in Europe to maintain leadership positions in biosimilars, keep and expand their manufacturing in Europe and improve access to these life-changing treatments for even more patients.
